ABNCoV2

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

ABNCoV2 is a cVLP COVID-19 vaccine candidate developed by Expres2ion Biotechnologies and Adaptvac, outlicensed to Bavarian Nordic. On 9 August 2021, it was announced that the first round of trials of the vaccine had been finalized with good results among 45 test subjects.

ABNCoV2 is a cVLP COVID-19 vaccine candidate developed by Expres2ion Biotechnologies and Adaptvac, outlicensed to Bavarian Nordic. On 9 August 2021, it was announced that the first round of trials of the vaccine had been finalized with good results among 45 test subjects.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1247436727 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

4 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.